Genentech Highlights Long-Term Data Across Hematology Portfolio at ASH 2024
核心洞察
Genentech will present over 40 abstracts at the ASH Annual Meeting, showcasing advancements in lymphoma (搜索) and other blood disorders (搜索).
Five-year data from the POLARIX study shows Polivy, combined with R-CHP, has a positive trend in overall survival for DLBCL (搜索) patients.
Extended follow-up data of Lunsumio and Columvi demonstrate long-lasting remissions and immune system recovery in follicular lymphoma (搜索) and DLBCL (搜索).
Genentech, a member of the Roche Group, is set to present more than 40 abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego, California. The data will highlight long-term follow-up results and new investigational combination data across nine blood disorders (搜索), reinforcing Genentech’s commitment to improving patient outcomes in lymphoma (搜索). Key presentations will feature updates on Polivy (polatuzumab vedotin-piiq), Lunsumio (mosunetuzumab-axgb), and Columvi (glofitamab-gxbm (搜索)), along with novel bispecific antibody combinations.
Polivy Demonstrates Durable Remissions in DLBCL
Five-year data from the Phase III POLARIX study (abstract #469) will be presented, reinforcing the potential of Polivy in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) to provide durable and lasting remissions. The study, for the first time, shows a positive trend in overall survival (OS) for patients with first-line diffuse large B-cell lymphoma (搜索) (DLBCL (搜索)), a significant advancement in a field with limited progress in nearly two decades. An observational study of Pola-R-CHP in previously untreated DLBCL patients (POLASTAR, abstract #4475) will also be presented.
Lunsumio and Columvi Show Long-Lasting Remissions
Extended follow-up data of up to four years from the pivotal GO29781 study of Lunsumio (abstract #4407) and NP30179 study of Columvi (abstract #865) will be shared. These data demonstrate long-lasting remissions and immune system recovery after the end of treatment, supporting the use of fixed-duration bispecific antibodies for third-line or later (3L+) follicular lymphoma (搜索) (FL (搜索)) and DLBCL (搜索), respectively. Additionally, the first presentation of data for a subcutaneous formulation of Lunsumio monotherapy from the pivotal Phase II GO29781 study (abstract #1645) will show high rates of deep and durable responses and low rates and severity of cytokine release syndrome (CRS) in people with 3L+ FL. Subcutaneously administered Lunsumio could improve the patient experience by combining shorter administration time with the existing benefits of a fixed-duration and outpatient therapy.
Quality of Life Improvements with Columvi
New patient-reported outcomes data from the Phase III STARGLO study (abstract #5132) indicate comparable health-related quality of life between treatment arms, despite a higher median number of cycles received with the Columvi combination (11 versus 4). These data, combined with the significant improvement in OS observed in the study, support the potential benefit for patients with second-line or later DLBCL (搜索).
Investigational Combinations with Polivy
New and updated data from investigational study combinations of Polivy with bispecific antibodies Lunsumio and Columvi in relapsed or refractory DLBCL (搜索), including the Phase Ib/II NP39488 (abstract #988) and Phase II GO40516 (abstract #989) studies, will be presented. These findings add to the growing body of evidence demonstrating the potential of novel bispecific antibody/Polivy combinations in earlier treatment lines, supporting their ongoing Phase III development.
Additional Highlights
Other notable presentations include data on Cevostamab in heavily pretreated relapsed/refractory multiple myeloma (搜索) (abstract #1021), and updates on Hemlibra in hemophilia A (搜索) (abstracts #1214, #5078), and PiaSky (crovalimab) in paroxysmal nocturnal hemoglobinuria (搜索) (PNH (搜索)) (abstracts #2687, #4078).